Advertisement
Screener

ANI PHARMACEUTICALS, INC (ANIP) Payments for Repurchase of Common Stock

2.8 / 5 stars · 68/120 Roast Me

ANI PHARMACEUTICALS, INC Payments for Repurchase of Common Stock

Shares the company repurchased and the cash it paid, as filed in its 10-Q and 10-K XBRL (statement of shareholders' equity and cash flow statement).

  • ANI PHARMACEUTICALS, INC payments for repurchase of common stock for the quarter ending 2026-06-30 was $813.00K, a 47.55% increase year-over-year.
  • ANI PHARMACEUTICALS, INC payments for repurchase of common stock for the quarter ending 2026-03-31 was $19.75M, a 97.49% increase year-over-year.
  • ANI PHARMACEUTICALS, INC payments for repurchase of common stock for the quarter ending 2025-12-31 was $611.00K, a 92.14% increase year-over-year.
  • ANI PHARMACEUTICALS, INC payments for repurchase of common stock for the quarter ending 2025-09-30 was $1.04M, a 53.53% increase year-over-year.
  • ANI PHARMACEUTICALS, INC payments for repurchase of common stock for fiscal 2025 was $12.21M, a 11.41% increase from fiscal 2024.
  • ANI PHARMACEUTICALS, INC payments for repurchase of common stock for fiscal 2024 was $10.96M, a 119.75% increase from fiscal 2023.
  • ANI PHARMACEUTICALS, INC payments for repurchase of common stock for fiscal 2023 was $4.99M, a 154.57% increase from fiscal 2022.
  • ANI PHARMACEUTICALS, INC payments for repurchase of common stock for fiscal 2022 was $1.96M, a 120.11% increase from fiscal 2021.
Period endPayments for Repurchase of Common Stock 3 monthPayments for Repurchase of Common Stock 12 month
2026-06-30$813.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-07
$22.22M
derived: sum of 4 quarters · filed 2026-08-07
2026-03-31$19.75M
10-Q · filed 2026-05-08
$21.96M
derived: sum of 4 quarters · filed 2026-08-07
2025-12-31$611.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27
$12.21M
10-K · filed 2026-02-27
2025-09-30$1.04M
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-07
$11.92M
derived: sum of 4 quarters · filed 2026-08-07
2025-06-30$551.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-07
$11.55M
derived: sum of 4 quarters · filed 2026-08-07
2025-03-31$10.00M
10-Q · filed 2026-05-08
$12.30M
derived: sum of 4 quarters · filed 2026-05-08
2024-12-31$318.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27
$10.96M
10-K · filed 2026-02-27
2024-09-30$680.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-07
$10.87M
derived: sum of 4 quarters · filed 2026-02-27
2024-06-30$1.30M
derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-08
$10.86M
derived: sum of 4 quarters · filed 2026-02-27
2024-03-31$8.66M
10-Q · filed 2025-05-09
$10.10M
derived: sum of 4 quarters · filed 2026-02-27
2023-12-31$231.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27
$4.99M
10-K · filed 2026-02-27
2023-09-30$670.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-08
$4.88M
derived: sum of 4 quarters · filed 2025-02-28
2023-06-30$537.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06
$4.44M
derived: sum of 4 quarters · filed 2025-02-28
2023-03-31$3.55M
10-Q · filed 2024-05-10
$4.39M
derived: sum of 4 quarters · filed 2025-02-28
2022-12-31$119.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-28
$1.96M
10-K · filed 2025-02-28
2022-09-30$239.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08
$1.84M
derived: sum of 4 quarters · filed 2024-02-29
2022-06-30$483.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09
$1.68M
derived: sum of 4 quarters · filed 2024-02-29
2022-03-31$1.12M
10-Q · filed 2023-05-08
$1.66M
derived: sum of 4 quarters · filed 2024-02-29
2021-12-31$1.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29
$890.00K
10-K · filed 2024-02-29
2021-09-30$73.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09
2021-06-30$468.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08
2021-03-31$348.00K
10-Q · filed 2022-05-10
2020-12-31$1.52M
10-K · filed 2023-03-09
2019-12-31$1.03M
10-K · filed 2022-03-15
2018-12-31$0.00
10-K · filed 2019-02-27
2017-12-31$0.00
derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-27
$0.00
10-K · filed 2019-02-27
2017-09-30$0.00
derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-02
$0.00
derived: sum of 4 quarters · filed 2019-02-27
2017-06-30$0.00
derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-03
$0.00
derived: sum of 4 quarters · filed 2019-02-27
2017-03-31$0.00
10-Q · filed 2017-05-04
$0.00
derived: sum of 4 quarters · filed 2019-02-27
2016-12-31$0.00
derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-27
$2.50M
10-K · filed 2019-02-27
2016-09-30$0.00
derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-02
$2.50M
derived: sum of 4 quarters · filed 2018-02-27
2016-06-30$0.00
derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-03
$2.50M
derived: sum of 4 quarters · filed 2018-02-27
2016-03-31$2.50M
10-Q · filed 2017-05-04
$2.50M
derived: sum of 4 quarters · filed 2018-02-27
2015-12-31$0.00
derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-27
$0.00
10-K · filed 2018-02-27
2015-09-30$0.00
derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-03
$0.00
derived: sum of 4 quarters · filed 2017-03-02
2015-06-30$0.00
derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-04
$0.00
derived: sum of 4 quarters · filed 2017-03-02
2015-03-31$0.00
10-Q · filed 2016-05-05
2014-12-31$0.00
derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-02
$0.00
10-K · filed 2017-03-02
2014-09-30$0.00
derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-10
2013-12-31$0.00
derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-23
$433.00K
10-K · filed 2016-02-23
2013-09-30$0.00
derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-10
2012-12-31$0.00
derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-28
$0.00
10-K · filed 2014-02-28
2012-09-30$0.00
derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-07

Similar stocks

Stock NameCountryMarket CapPE Ratio
COMPASS Pathways plc (CMPS)$1.812B-4.87
Septerna, Inc. (SEPN)United States$1.783B-63.01
Xencor Inc (XNCR)United States$1.776B-7.33
Zymeworks Inc. (ZYME)United States$1.902B-12.44
Eton Pharmaceuticals, Inc. (ETON)United States$1.701B80.74
Sarepta Therapeutics, Inc. (SRPT)United States$1.941B-13.89
AGIOS PHARMACEUTICALS, INC. (AGIO)United States$1.962B-5.38
Xeris Biopharma Holdings, Inc. (XERS)United States$1.632B-80.10
Stoke Therapeutics, Inc. (STOK)United States$1.630B-9.82
Biohaven Ltd. (BHVN)United States$1.990B-3.83